Weeding: Bayer shares rise: EPA re-examines glyphosate – Bayer wins another lawsuit | news

On Friday (local time) in San Francisco, the court classified the EPA’s assessment that the active ingredient in Bayer’s controversial Roundup herbicide poses no particular danger to humans as questionable. The subject is of great importance to the Bayer pharmaceutical and chemical group. It is facing numerous US lawsuits in the United States for alleged cancer risks due to glyphosate. But on Friday there was also some good news for the DAX company: in one case in the state of Oregon, it got another success in court. Bayer has now won the last four US lawsuits involving plaintiffs blaming glyphosate for cancer.

The EPA last looked at the herbicide in 2020 and said it posed no health risk when used correctly. The environmental organization NRDC, among other things, has complained about this. “For years, the EPA has refused to do anything about the harmful effects of this pesticide on humans and the environment,” the organization said Friday. The court made it clear that this could not be the case.

In its ruling, the competent appeals court was particularly bothered by the EPA’s justification that glyphosate is not carcinogenic. The background analysis is “incorrect” and not in line with the agency’s guidelines. The EPA declined to comment on the criticism when asked. A spokesperson said the glyphosate decision will be reviewed.

In a statement, Bayer expressed confidence that the EPA found no cancer risks from glyphosate even in a new review. Last time, the US government’s environmental agency acted conscientiously and carried out a “rigorous” evaluation of scientific studies from the past 40 years. Bayer took on the glyphosate lawsuits with the $ 60 billion acquisition of seed giant Monsanto in 2018.

The numerous procedures in the USA are based in particular on an evaluation by the International Agency for Research on Cancer of the World Health Organization. In 2015, it classified Monsanto’s herbicide as “possibly carcinogenic” to humans. Bayer rejects this and argues with the approval of many regulators and studies that aim to prove that glyphosate is safe when used as directed.

The tide has finally turned after Bayer lost its top three glyphosate lawsuits in the United States. On Friday the Dax group won the fourth consecutive procedure. The Jackson County, Oregon Grand Jury found Roundup unanimously not responsible for plaintiff’s cancer. “We remain fully committed to Roundup’s safety,” Bayer said. The group announced that it would “defend itself with confidence” in all future legal conflicts on the matter.

Verdict expected in the trial for damage to glyphosate honey

After more than two years of litigation, the Frankfurt (Oder) regional court is expected to hear the verdict in a beekeeper’s lawsuit against a farm this Monday (12:00). The reason is the use of the controversial herbicide glyphosate. In the process, the beekeeper demands compensation for his tainted honey. A verdict in favor of the beekeeper would have a signal effect on agriculture and politics. According to the Aurelia Foundation, which claims the plaintiff, beekeepers were mostly left with the damage caused by others if their honey was contaminated with pesticides from agriculture.

In the spring of 2019, the beekeeper set up his hives next to an area managed by the farm. At the end of April 2019, the company treated the area with herbicides containing glyphosate. Bees carried glyphosate-contaminated nectar or pollen to the hive. Wax and four tons of honey had to be destroyed. According to his own statements, the beekeeper had to give up his business.

According to the Aurelia Foundation, subsequent laboratory analyzes of honey showed that the maximum residue levels allowed for glyphosate were exceeded by a factor of up to 152. According to its own statements, the foundation is committed to nature conservation, in particular in bees and bee-friendly agriculture.

Bayer shares temporarily increased 1.31% in XETRA trading to EUR 63.37 on Monday.


Leveraged products selected on BayerWith knock-outs, speculative investors can participate disproportionately in price movements. Simply select the leverage you want and we’ll show you the suitable open end products on Bayer

The leverage must be between 2 and 20

No data

More Bayer news

Image sources: Taina Sohlman /

About the author


Leave a Comment